News >

Updated OS Data Reported With Tivozanib in Highly Refractory Metastatic RCC

Gina Columbus @ginacolumbusonc
Published: Tuesday, Sep 10, 2019

Sumanta K. Pal, MD, of City of Hope

Sumanta K. Pal, MD

Results from the second prespecified analysis of the TIVO-3 trial showed a hazard ratio for overall survival (OS) of 0.99 for tivozanib (Fotivda) compared with sorafenib (Nexavar) in patients with highly refractory metastatic renal cell carcinoma (RCC), according to AVEO Oncology, the developer of tivozanib.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x